21.11.2023 07:30:14 CET | Demant A/S |
Intern viden
Selskabsmeddelelse nr. 2023-14 21. november 2023
Demant genoptager aktietilbagekøb
Det er tidligere blevet meldt ud, at koncernen måske ville genoptage sit aktietilbagekøb i 2023. I tråd med dette meddeler Demant i dag, at man har besluttet at genoptage sit aktietilbagekøb, hvilket afspejler en betydelig reduktion af gearingen i løbet af 2023 takket være et stærkt cashflow igennem hele året. Derudover har opkøbsniveauet været lavere end oprindeligt planlagt, idet nogle opkøb nu forventes at blive lukket i 2024.
Der er ingen ændringer i koncernens forventninger til 2023, og gearing-multiplen (NIBD/EBITDA) ved udgangen af 2023 forventes stadig at være inden for vores mellemlange til langsigtede mål på 2,0-2,5.
Yderligere information:
Søren Nielsen, koncernchef og adm. direktør
Telefon +45 3917 7300
www.demant.com
Øvrige kontaktpersoner:
René Schneider, CFO
Mathias Holten Møller, Head of Investor Relations
Peter Pudselykke, Investor Relations Officer
Henrik Axel Lynge Buchter, Manager of External Communication
Kontakter
Henrik Axel Lynge Buchter, External Communication Manager, Corporate Communication & Sustainability, +45 2264 9982, heey@demant.com
Om Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.
Vedhæftninger
2023-14 Demant genoptager aktietilbagekøb.pdf
21.11.2023 07:30:14 CET | Demant A/S |
Inside information
Company announcement no 2023-14 21 November 2023
Demant to resume share buy-backs
It has previously been announced that the Group may resume its share buy-backs in 2023. In line with this, Demant announces today that it has decided to resume its share buy-backs following material deleveraging during 2023 thanks to strong cash flow generation throughout the year. Also, the level of acquisitions has been lower than originally planned, as some acquisitions are now expected to close in 2024.
There are no changes to the Group’s outlook for 2023, and the gearing multiple (NIBD/EBITDA) at the end of 2023 is still expected to be within the medium- to long-term target of 2.0-2.5.
Further information:
Søren Nielsen, President & CEO
Phone +45 3917 7300
www.demant.com
Other contacts:
René Schneider, CFO
Mathias Holten Møller, Head of Investor Relations
Peter Pudselykke, Investor Relations Officer
Henrik Axel Lynge Buchter, Manager of External Communication
Contacts
Henrik Axel Lynge Buchter, External Communication Manager, Corporate Communication & Sustainability, +45 2264 9982, heey@demant.com
About Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.
Attachments
2023-14 Demant to resume share buy-backs.pdf
